<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05611268</url>
  </required_header>
  <id_info>
    <org_study_id>CAAE 57562322.5.0000.0068</org_study_id>
    <nct_id>NCT05611268</nct_id>
  </id_info>
  <brief_title>Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome</brief_title>
  <official_title>Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome: a Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>InCor Heart Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sao Paulo General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial&#xD;
      hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia,&#xD;
      with an increase in erythrocyte mass, which predisposes to thrombotic complications.&#xD;
      Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with&#xD;
      described effects of reduction in erythrocyte and platelet aggregation, adhesion and&#xD;
      activation of leukocytes, and endothelial damage. The main objective of this study is to&#xD;
      verify if the chronic oral administration of pentoxifylline to Eisenmenger patients induces&#xD;
      an increase in the circulating levels of thrombomodulin, a naturally occurring proteoglycan&#xD;
      with anticoagulant, anti thrombotic and anti-inflammatory properties.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial&#xD;
      hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia,&#xD;
      with an increase in erythrocyte mass, which predisposes to thrombotic complications. It also&#xD;
      involves endothelial dysfunction characterized by increase in the circulating levels of von&#xD;
      Willebrand factor, tissue-type plasminogen activator and P-selectin, with a reduction in the&#xD;
      plasma concentration of thrombomodulin. The usual drug treatment is represented by the use of&#xD;
      prostanoids, endothelin receptor antagonists, phosphodiesterase-5 inhibitors and, eventually,&#xD;
      anticoagulation with warfarin. However, the difficulty of controlling the chronic use of&#xD;
      warfarin and the few studies with other oral anticoagulants, brings the possibility of using&#xD;
      drugs not specifically designated as coagulation inhibitors, such as pentoxifylline. This&#xD;
      drug is a xanthine derivative and it is considered as a hemorrheological agent with described&#xD;
      effects of reduction in erythrocyte and platelet aggregation, adhesion and activation of&#xD;
      leukocytes, and endothelial damage. It is, therefore, considered as an agent capable of&#xD;
      reducing blood viscosity and improving erythrocyte deformability probably due to an increase&#xD;
      in intracellular adenosine triphosphate (ATP), with a reduction in Ca++ and phosphorylation&#xD;
      of membrane proteins. The objective of this study is to verify if the chronic oral&#xD;
      administration of pentoxifylline: 1) induces an increase in the circulating levels of&#xD;
      thrombomodulin, a naturally occurring proteoglycan with anticoagulant, anti thrombotic and&#xD;
      anti-inflammatory properties; 2) stabilizes or induces a reduction in circulating tissue&#xD;
      factor and thrombin-antithrombin complexes; 3) changes the expression of thrombomodulin and&#xD;
      tissue factor in circulating monocytes; 4) offers protection against the occurrence of&#xD;
      predefined clinical events; 5) provides improvement in physical capacity, peripheral oxygen&#xD;
      saturation, hematocrit level and right ventricular function. The main study outcome is&#xD;
      biochemical: change from baseline (increase) in circulating levels of thrombomodulin at 3&#xD;
      months and 6 months of oral use of pentoxifylline. It will be a prospective, single-center,&#xD;
      randomized study. Forty-eight adult patients with Eisenmenger syndrome who are already using&#xD;
      specific therapies for pulmonary arterial hypertension will be included and these will be&#xD;
      randomized to receive pentoxifylline as an adjunctive treatment or remain under routine&#xD;
      therapeutic measures for pulmonary arterial hypertension. Oral pentoxifylline will be started&#xD;
      at the dose of 400 mg/day for 30 days, followed by 800 mg/day for 5 months, completing the&#xD;
      6-month period of the study. The routine treatment for pulmonary arterial hypertension will&#xD;
      be maintained for all patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 3, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The professional responsible for obtainment of laboratory data including outcome measures will not have access to any clinical data or patient allocation to the study groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration of Thrombomodulin</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in plasma concentration of thrombomoduin at 3 months and 6 months of pentoxifylline therapy compared to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of tissue factor</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in plasma concentration of tissue factor at 3 months and 6 months of pentoxifylline therapy compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte thrombomodulin content</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in mean fluorescence intensity (MFI) for thrombomodulin in circulating (blood) monocytes measured by flow cytometry 3 months and 6 months of pentoxifylline therapy compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocyte tissue factor content</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in mean fluorescence intensity (MFI) for tissue factor in circulating (blood) monocytes measured by flow cytometry 3 months and 6 months of pentoxifylline therapy compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of other markers of thrombosis</measure>
    <time_frame>3 months and 6 months</time_frame>
    <description>Change in plasma concentration of D-dimer and thrombin-antithrombin complexes at 3 months and 6 months of pentoxifylline therapy compared to baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Eisenmenger Syndrome</condition>
  <arm_group>
    <arm_group_label>No treatment group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>24 patients that will continue receiving routine treatment for PAH</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>24 patients that will receive pentoxifylline and the routine treatment for PAH</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>Oral Pentoxifylline 400 mg/day for 30 days, followed by 800 mg/day for 150 days</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eisenmenger syndrome in functional class II, III or IV (World Health Organization for&#xD;
             Pulmonary Hypertension).&#xD;
&#xD;
          2. Using or not oral anticoagulation with warfarin.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Hospitalized.&#xD;
&#xD;
          2. History of relevant and/or repetitive bleeding.&#xD;
&#xD;
          3. Relevant comorbidities with specific treatments.&#xD;
&#xD;
          4. Systemic syndromes, except Down syndrome.&#xD;
&#xD;
          5. Candidates for surgical treatment of any nature, except dental.&#xD;
&#xD;
          6. Clinically manifest systemic infectious or inflammatory disease.&#xD;
&#xD;
          7. Thrombocytopenia (&lt;80x10*9 platelets/L).&#xD;
&#xD;
          8. Patients in chronic anticoagulation regimen other than warfarin.&#xD;
&#xD;
          9. Diabetics individuals.&#xD;
&#xD;
         10. Pregnancy in progress, interruption of contraception or amenorrhea.&#xD;
&#xD;
         11. History of intolerance of pentoxifylline or other xanthine derivatives.&#xD;
&#xD;
         12. &quot;Creatinine clearance&quot; less than or equal to 30 mL/minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Augusto Barbosa Lopes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>InCor Heart Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Augusto Barbosa Lopes, MD</last_name>
    <phone>+55 11 2661-5409</phone>
    <email>aablopes@usp.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariana Cappelletti Galante, PharmD</last_name>
    <phone>+55112661-5709</phone>
    <email>Mariana.galante@hc.fm.usp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antonio Augusto Barbosa Lopes</name>
      <address>
        <city>SÃ£o Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MarianaCappelletti Galante, PharmD</last_name>
      <phone>+55 11 2661-5709</phone>
      <phone_ext>PharmD</phone_ext>
      <email>Mariana.galante@hc.fm.usp.br</email>
    </contact>
    <investigator>
      <last_name>Nair Maeda, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2022</verification_date>
  <study_first_submitted>August 24, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2022</study_first_posted>
  <last_update_submitted>November 3, 2022</last_update_submitted>
  <last_update_submitted_qc>November 3, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>Congenital Heart Disease</keyword>
  <keyword>Thrombosis</keyword>
  <keyword>Pentoxifylline</keyword>
  <keyword>Thrombomodulin</keyword>
  <keyword>Tissue Factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eisenmenger Complex</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

